NF Midwest Collaborates to Fund NF2 Gene Therapy Research
NF Midwest, NF Northeast and NF2 BioSolutions have joined forces to fund an NF2 Gene Therapy Research Study at the Mueller Lab at the Gene Therapy Center, UMass Medical School. This $65,000 grant will be used to design, manufacture and test potential gene therapy vectors for Neurofibromatosis Type 2. Dr. Katharina Meijboom, a postdoctoral researcher, is heading up the project. Her research will focus on several different approaches and will be tested in both cell lines and mouse models. The Mueller Laboratory at the UMass Gene Therapy Center has a long history of using recombinant AAV as a platform for gene therapy in a plethora of different diseases, ranging from liver diseases to central nervous system diseases, such as ALS.
Offered by: University of Colorado AnschutzConducted by: Katelyn Glowinski, genetic counseling student, master’s program This research study is designed to gain a better understanding of healthcare barriers faced by adults with Neurofibromatosis Type 1 (NF1), as well as evaluate any associations between these barriers and your self-reported neuropsychiatric or mental health status. If you join... Read More
Rachel was 13 when she first attended Camp NF. At an age when so much was changing, camp gave her something she deeply needed: the chance to meet other young people who understood life with NF. “NF camp gave me the opportunity to connect with others who had a shared experience and come to understand... Read More
Responses